RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionAnd do you remember how pelareorep's effectiveness could serve as a predictive diagnostic to the synergistic addition immune checkpoint inhibitors for an effective immuno-oncology combination therapy ? Well I have tried to explain how and why ONCY has an advantage that few other oncology companies have and to educate the naysayers on this novel, innovative and effective therapy.